Home > Once-weekly insulin is a promising treatment option

Once-weekly insulin is a promising treatment option

Presented By
Dr Julio Rosenstock, University of Texas Southwestern, USA
Conference
EASD 2020
Trial
Phase 2
The once-weekly basal insulin analogue, icodec, showed comparable efficacy and safety to once-daily insulin glargine U100 in a phase 2 study (NCT03751657). Patients with type 2 diabetes who need basal insulin could potentially have a simpler, once-weekly treatment regimen without compromising blood sugar control and safety. The investigational drug, insulin icodec, is a long-acting basal insulin analogue with a half-life of approximately 1 week. After injection, insulin icodec binds strongly but reversibly to albumin, resulting in a slow and steady release of active icodec that lowers blood sugar throughout the week. As it is a concentrated formulation, icodec’s injection volume is equivalent to that of daily glargine U100. Dr Julio Rosenstock (University of Texas Southwestern, USA) and colleagues...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on